LeMaitre Vascular, Inc.
NASDAQ:LMATMedical - Instruments & Supplies
+$1.60 today
- Market cap
- $1.73B
- Beta
- 0.52
- P/E (TTM)
- 34.3
- EPS (TTM)
- $2.74
- Dividend yield
- 0.96%
Volume 0.22M
Average 0.26M
LMAT Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
LeMaitre Vascular, Inc.NASDAQ: LMAT
Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026
Accounts receivables declines year over year
Q1 FY2026 accounts receivables of $2.48M (cash outflow) fell 46.3% year over year, ahead of the -84.7% change in trailing-twelve-month accounts receivables. Sequentially, it rose 60.7% from the prior quarter. Over 3 fiscal years it compounded at -5.9% a year.
Context
- Accounts receivables amounted to 1.2% of revenue in FY2025, down 1.7 pp from a year earlier.
- Accounts receivables grew in size in 1 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -46.3% holds above the trailing-twelve-month pace of -84.7%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- (2.95M) USD
- Year-over-year change
- +54.1%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (2.95M) | +54.1% |
| FY2024 | 2024-12-31 | (6.42M) | -104.7% |
| FY2023 | 2023-12-31 | (3.14M) | +11.3% |
| FY2022 | 2022-12-31 | (3.53M) | -331.9% |
| FY2021 | 2021-12-31 | (818K) | — |
Accounts Receivables vs competitors
How LMAT compares with its peers on the latest reported figures
- LMAT's LTM Mar 2026 accounts receivables of $809K is the smallest of the 8 companies compared; the peer median is $17.77M.
- Its year-over-year change of -84.7% is the 5th highest of 8, against a peer median of -15.4%.
- Accounts receivables amounts to 0.3% of revenue for LMAT, versus a peer median of 0.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $293M | +144.2% | +6.9% | 1.4% | |
| LTM Jul 2026 | $264M | +3.5% | -29.7% | 0.7% | |
| LTM Jun 2026 | $67.5M | +15.6% | +30.5% | 2.6% | |
| LTM Jun 2026 | $17.77M | -172.9% | -34.6% | 1.2% | |
| LTM Sep 2026 | $9.85M | -15.4% | -43.5% | 0.6% | |
| LTM Feb 2026 | $2.4M | -146.8% | — | 0.8% | |
| LTM Mar 2026 | $2.11M | -89.5% | -18.3% | 0.5% | |
| LTM Mar 2026 | $809K | -84.7% | -5.9% | 0.3% | |
| Peer median (excluding LMAT) | $17.77M | -15.4% | -24.0% | 0.8% | |
Competitors are the stored peer set for LMAT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 26.91M | 20.64M | 30.11M | 44.04M | 57.73M |
| Depreciation & Amortization | 11.07M | 9.43M | 9.52M | 9.67M | 10.42M |
| Deferred Income Tax | 79K | (182K) | 783K | (451K) | 2.31M |
| Stock-Based Compensation | 3.48M | 4.17M | 5.32M | 6.57M | 7.83M |
| Change in Working Capital | (9.96M) | (13.4M) | (11.25M) | (20.1M) | (1.75M) |
| Accounts Receivables | (818K) | (3.53M) | (3.14M) | (6.42M) | (2.95M) |
| Inventory | (5.49M) | (7.42M) | (9.79M) | (10.57M) | (7.22M) |
| Accounts Payables | (1.73M) | 645K | 4.6M | (779K) | 4.2M |
| Other Working Capital | (1.93M) | (3.1M) | (2.92M) | (2.33M) | 4.22M |
| Other Non-Cash Items | 3.53M | 4.72M | 2.28M | 4.4M | 4.71M |
| Operating Cash Flow | 35.1M | 25.38M | 36.75M | 44.12M | 81.25M |
| Capital Expenditures | (4.88M) | (3.23M) | (7.27M) | (6.96M) | (6.78M) |
| Acquisitions (Net) | 0 | 0 | (899K) | 0 | (1.9M) |
| Purchases of Investments | (59.19M) | (8M) | (16.55M) | (277.94M) | (641.33M) |
| Sales of Investments | 3M | 0 | 0 | 84.78M | 585.07M |
| Other Investing Activities | 0 | 858K | 0 | 0 | 0 |
| Investing Cash Flow | (61.08M) | (10.37M) | (24.72M) | (200.12M) | (64.94M) |
| Debt Repayment | (39M) | 0 | 0 | 169.27M | 0 |
| Common Stock Issued | 63.24M | 3.47M | 6.17M | 6.44M | 6.82M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | (9.34M) | (10.99M) | (12.45M) | (14.38M) | (18.11M) |
| Other Financing Activities | (1.2M) | (1.71M) | (853K) | (3.23M) | (3.25M) |
| Financing Cash Flow | 13.7M | (9.23M) | (7.13M) | 158.1M | (14.54M) |
| Effect of Forex Changes | (637K) | (494K) | 230K | (765K) | 864K |
| Net Change in Cash | (12.91M) | 5.28M | 5.14M | 1.34M | 2.63M |
| Free Cash Flow | 30.22M | 22.15M | 29.49M | 37.16M | 74.47M |
LeMaitre Vascular, Inc.
NASDAQ:LMAT
Intrinsic Alpha fair value
Locked
Current Price
$75.58
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.